Merck enters Nanobody alliance with Ablynx for ion channel modulators
Merck & Co. Inc. has entered into an agreement with Ablynx NV (therapeutic proteins and antibodies) to develop new ion channel modulators using Ablynx’s Nanobody technology.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.